Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 6, 2013, Pages

  Brettschneider, Johannes ^a   Kurent, Jerome ^b   Ludolph, Albert ^a  

^a UNIVERSITY OF ULM   (Germany)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE EVENT; AMYOTROPHIC LATERAL SCLEROSIS; ANALGESIA; DRUG EFFICACY; DRUG THERAPY; HUMAN; MOTOR NEURON DISEASE; OUTCOME ASSESSMENT; PAIN; PAIN ASSESSMENT; PAIN INTENSITY; PALLIATIVE THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL; SYSTEMATIC REVIEW; ADULT; COMPLICATION;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; HUMANS; MOTOR NEURON DISEASE; PAIN;

EID: 84891716939     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD005226.pub3     Document Type: Review

References (59)

1. Abe Y, Miyashita M, Ito N, Shirai Y, Momose Y, Ichikawa Y, et al.Attitude of outpatients with neuromuscular diseases in Japan to pain and use of analgesics. Journal of the Neurological Sciences 2008;267(1-2):22-7. [PUBMED: 17916366]
2. Adelman EE, Albert SM, Rabkin JG, Del Bene ML, Tider T, O'Sullivan I. Disparities in perceptions of distress and burden in ALS patients and family caregivers. Neurology 2004;62(10):1766-70. [PUBMED: 15159475]
3. Amtmann D, Weydt P, Johnson KL, Jensen MP, Carter GT. Survey of cannabis use in patients with amyotrophic lateral sclerosis. American Journal of Hospice and Palliative Care 2004;21(2):95-104. [PUBMED: 15055508]
4. Bedlack RS, Pastula DM, Hawes J, Heydt D. Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease. Amyotrophic Lateral Sclerosis 2009;10(4):210-5. [PUBMED: 18821142]
5. Borasio GD, Shaw PJ, Hardiman O, Ludolph AC, Sales Luis ML, Silani V, European ALS Study Group. Standards of palliative care for patients with amyotrophic lateral sclerosis: results of a European survey. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2001;2(3):159-64. [PUBMED: 11771773]
6. Bradley WG, Anderson F, Bromberg M, Gutmann L, Harati Y, Ross M, et al.ALS CARE Study Group. Current management of ALS: comparison of the ALS CARE Database and the AAN Practice Parameter. The American Academy of Neurology. Neurology 2001;57(3):500-4. [PUBMED: 11502920]
7. Carter GT, Abood ME, Aggarwal SK, Weiss MD. Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials. The American Journal of Hospice and Palliative Care 2010;27(5):347-56. [PUBMED: 20439484]
8. Chiò A, Silani V, Italian ALS Study Group. Amyotrophic lateral sclerosis care in Italy: a nationwide study in neurological centers. Journal of the Neurological Sciences 2001;191(1-2):145-50. [PUBMED: 11677006]
9. de Carvalho M. Gabapentin for the treatment of spasticity in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2001;2(1):47-8. [PUBMED: 11465933]
10. de Castro-Costa CM, Oria RB, Machado-Filho JA, Franco MT, Diniz DL, Giffoni SD, et al.Amyotrophic lateral sclerosis. Clinical analysis of 78 cases from Fortaleza (northeastern Brazil). Arquivos de Neuro-Psiquiatria 1999;57(3B):761-74. [PUBMED: 10751910]
11. Drake ME Jr. Chronic pain syndrome in amyotrophic lateral sclerosis. Archives of Neurology 1983;40(7):453-4. [PUBMED: 6860189]
12. Forshew DA, Bromberg MB. A survey of clinicians' practice in the symptomatic treatment of ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2003;4(4):258-63. [PUBMED: 14753660]
13. Ganzini L, Johnston WS, McFarland BH, Tolle SW, Lee MA. Attitudes of patients with amyotrophic lateral sclerosis and their care givers toward assisted suicide. New England Journal of Medicine 1998;339(14):967-73. [PUBMED: 9753713]
14. Ganzini L, Johnston WS, Hoffman WF. Correlates of suffering in amyotrophic lateral sclerosis. Neurology 1999;52(7):1434-40. [PUBMED: 10227631]
15. Ganzini L, Silveira MJ, Johnston WS. Predictors and correlates of interest in assisted suicide in the final month of life among ALS patients in Oregon and Washington. Journal of Pain and Symptom Management 2002;24(3):312-7. [PUBMED: 12458112]
16. Ganzini L, Johnston WS, Silveira MJ. The final month of life in patients with ALS. Neurology 2002;59(3):428-31. [PUBMED: 12177378]
17. Hecht M, Hillemacher T, Grasel E, Tigges S, Winterholler M, Heuss D, et al.Subjective experience and coping in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2002;3(4):225-31. [PUBMED: 12710513]
18. Jensen MP, Abresch RT, Carter GT, McDonald CM. Chronic pain in persons with neuromuscular disease. Archives of Physical Medicine and Rehabilitation 2005;86(6):1155-63. [PUBMED: 15954054]
19. Maessen M, Veldink JH, van den Berg LH, Schouten HJ, van der Wal G, Onwuteaka-Philipsen BD. Requests for euthanasia: origin of suffering in ALS, heart failure, and cancer patients. Journal of Neurology 2010;257(7):1192-8. [PUBMED: 20148336]
20. Mandler RN, Anderson FA Jr, Miller RG, Clawson L, Cudkowicz M, Del Bene M, ALS C.A.R.E. Study Group. The ALS Patient Care Database: insights into end-of-life care in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2001;2(4):203-8. [PUBMED: 11958732]
21. McClelland S 3rd, Bethoux FA, Boulis NM, Sutliff MH, Stough DK, Schwetz KM, et al.Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief. Muscle and Nerve 2008;37(3):396-8. [PUBMED: 17894358]
22. Neudert C, Oliver D, Wasner M, Borasio GD. The course of the terminal phase in patients with amyotrophic lateral sclerosis. Journal of Neurology 2001;248(7):612-6. [PUBMED: 11518004]
23. Newrick PG, Langton-Hewer R. Motor neurone disease: can we do better? A study of 42 patients. British Medical Journal 1984;289(6444):539-42. [PUBMED: 6235890]
24. Newrick PG, Langton-Hewer R. Pain in motor neuron disease. Journal of Neurology, Neurosurgery, and Psychiatry 1985;48(8):838-40. [PUBMED: 4031936]
25. O'Brien T, Kelly M, Saunders C. Motor neuron disease: a hospice perspective. BMJ 1992;304(6825):471-3. [PUBMED: 1547416]
26. Oliver D. The quality of care and symptom control - the effects on the terminal phase of ALS/MND. Journal of the Neurological Sciences 1996;139 Suppl:134-6. [PUBMED: 8899674]
27. Oliver D. Opioid medication in the palliative care of motor neurone disease. Palliative Medicine 1998;12(2):113-5. [PUBMED: 9616447]
28. Saunders C, Walsh TD, Smith M. Hospice care in motor neuron disease. In: Saunders C, Summers DH, Teller N editor(s). Hospice: The Living Idea. London: Edward Arnold, 1981. [: 0713143983]
29. Shibata M, Abe K, Jimbo A, Shimizu T, Mihara M, Sadahiro S, et al.Complex regional pain syndrome type I associated with amyotrophic lateral sclerosis. Clinical Journal of Pain 2003;19(1):69-70. [PUBMED: 12514459]
30. Tedman BM, Young CA, Williams IR. Assessment of depression in patients with motor neuron disease and other neurologically disabling illness. Journal of the Neurological Sciences 1997;152(Suppl 1):S75-9. [PUBMED: 9419059]
31. Trail M, Nelson ND, Van JN, Appel SH, Lai EC. A study comparing patients with amyotrophic lateral sclerosis and their caregivers on measures of quality of life, depression, and their attitudes toward treatment options. Journal of the Neurological Sciences 2003;209(1-2):79-85. [PUBMED: 12686407]
32. Weber M, Goldman B, Truniger S. Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial. Journal of Neurology, Neurosurgery and Psychiatry 2010;81(10):1135-40. [PUBMED: 20498181]
33. Winter Y, Schepelmann K, Spottke AE, Claus D, Grothe C, Schröder R, et al.Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy. Journal of Neurology 2010 Apr 10 [Epub ahead of print];257(9):1473-81. [PUBMED: 20383521]
34. Wu PY. The management of patients with advanced motor neuron disease. Zhonghua Yi Xue Za Zhi 1998;61(3):141-5. [PUBMED: 9556945]
35. Ashworth NL, Satkunam LE, Deforge D. Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD004156.pub3]
36. Baldinger R, Katzberg HD, Weber M. Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD004157.pub2]
37. Borasio GD, Voltz R. Palliative care in amyotrophic lateral sclerosis. Journal of Neurology 1997;244(Suppl 4):S11-7. [PUBMED: 9402548]
38. Borasio GD, Voltz R, Miller RG. Palliative care in amyotrophic lateral sclerosis. Neurologic Clinics 2001;19(4):829-47. [PUBMED: 11854102]
39. Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2000;1(5):293-9. [PUBMED: 11464847]
40. Brownell B, Oppenheimer DR, Hughes JT. The central nervous system in motor neurone disease. Journal of Neurology, Neurosurgery, and Psychiatry 1970;33(3):338-57. [PUBMED: 5431724]
41. Clarke DM, McLeod JE, Smith GC, Trauer T, Kissane DW. A comparison of psychosocial and physical functioning in patients with motor neurone disease and metastatic cancer. Journal of Palliative Care 2005;21(3):173-9. [PUBMED: 16334972]
42. Coderre TJ, Kumar N, Lefebvre CD, Yu JS. A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. Journal of Neurochemistry 2007;100(5):1289-99. [PUBMED: 17241130]
43. Drory VE, Goltsman E, Reznik JG, Mosek A, Korczyn AD. The value of muscle exercise in patients with amyotrophic lateral sclerosis. Journal of the Neurological Sciences 2001;191(1-2):133-7. [PUBMED: 11677004]
44. El-Tawil S, Al Musa T, Valli H, Lunn MPT, El-Tawil T, Weber M. Quinine for muscle cramps. Cochrane Database of Systematic Reviews 2010, Issue 12. [DOI: 10.1002/14651858.CD005044.pub2]
45. US Food, Drug Administration. FDA orders unapproved quinine drugs from the market and cautions consumers about 'off-label' use of quinine to treat leg cramps. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108799.htm 2006.
46. US Food, Drug Administration. FDA Drug Safety Communication: new risk management plan and patient Medication Guide for Qualaquin (quinine sulfate). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm218202.htm 2010 (accessed 17 April 2013).
47. Gubbay SS, Kahana E, Zilber N, Cooper G, Pintov S, Leibowitz Y. Amyotrophic lateral sclerosis. A study of its presentation and prognosis. Journal of Neurology 1985;232(5):295-300. [PUBMED: 4056836]
48. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. Available from www.cochrane-handbook.org.
49. Lawyer TJr, Netsky MG. Amyotrophic lateral sclerosis. A. M. A. Archives of Neurology and Psychiatry 1953;69(2):171-92. [PUBMED: 13007227]
50. Lou JS, Reeves A, Benice T, Sexton G. Fatigue and depression are associated with poor quality of life in ALS. Neurology 2003;60(1):122-3. [PUBMED: 12525733]
51. Miller RG, Rosenberg JA, Gelinas DF, Mitsumoto H, Newman D, Sufit R, et al.Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 1999;52(7):1311-23. [PUBMED: 10227612]
52. Miller RG, Moore DH 2nd, Gelinas DF, Dronsky V, Mendoza M, Barohn RJ, et al.Western ALS Study Group. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001;56(7):843-8. [PUBMED: 11294919]
53. Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G. Riluzole in the treatment of mood and anxiety disorders. CNS Drugs 2008;22(9):761-86. [PUBMED: 18698875]
54. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) [Computer Program]. Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
55. Sung B, Lim G, Mao J. Altered expression and uptake activity of spinal glutamate transporters after nerve injury contribute to the pathogenesis of neuropathic pain in rats. Journal of Neuroscience 2003;23(7):2899-910. [PUBMED: 12684477]
56. Cancer pain relief and palliative care. Report of a WHO Expert Committee. World Health Organization Technical Report Series 1990; Vol. 804:1-75. [PUBMED: 1702248]
57. Worms PM. The epidemiology of motor neuron diseases: a review of recent studies. Journal of the Neurological Sciences 2001;191(1-2):3-9. [PUBMED: 11676986]
58. Brettschneider J, Ludolph A, Mitchell JD. Drug therapy for pain in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD005226]
59. Brettschneider J, Kurent J, Ludolph A, Mitchell J. Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD005226.pub2]